Ironwood Pharmaceuticals' Phase II STARGAZE trial reports positive results for apraglutide in treating steroid-refractory gastrointestinal acute graft-versus-host disease.
Ironwood Pharmaceuticals reported positive Phase II STARGAZE trial results for apraglutide, a GLP-2 analog, in treating steroid-refractory gastrointestinal acute graft-versus-host disease (SR GI aGVHD). The trial, involving 31 patients, demonstrated safety, tolerability, and response in the majority of patients. The study will continue for two years to evaluate long-term safety and efficacy.
March 28, 2024
3 Articles